Treanda® (bendamustine) – New Warning

- On October 18, 2016, the FDA approved new updates to the *Warnings and Precautions* section of the Treanda (bendamustine) drug label pertaining to hepatotoxicity.

- Treanda is indicated for:

  — The treatment of patients with chronic lymphocytic leukemia. Efficacy relative to first line therapies other than Leukeran® (chlorambucil) has not been established.
  — The treatment of patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with Rituxan® (rituximab) or a rituximab-containing regimen.

- Fatal and serious cases of liver injury have been reported with Treanda. Most cases were reported within the first three months of starting therapy.

  — Combination therapy, progressive disease or reactivation of hepatitis B were confounding factors in some patients.
  — Liver chemistry tests should be monitored prior to and during Treanda therapy.

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News® is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.